Delaware SB120 mandates health insurance coverage for biomarker testing in individual, group, and health benefit plans.

Delaware SB120 amends Titles 18, 29, and 31 of the Delaware Code to require health insurance coverage for biomarker testing. This testing, which includes analysis of tissue, blood, or other biospecimens, is mandated for diagnosis, treatment, management, or monitoring of diseases or conditions when supported by medical and scientific evidence. The bill specifies that coverage must be provided in a manner that minimizes disruptions in care, such as avoiding multiple biopsies. The requirements apply to individual, group, and health benefit plans, excluding certain limited benefit policies.

Delaware SB120 mandates health insurance coverage for biomarker testing in individual, group, and health benefit plans.

Delaware SB120 amends Titles 18, 29, and 31 of the Delaware Code to require health insurance coverage for biomarker testing. This testing, which includes analysis of tissue, blood, or other biospecimens, is mandated for diagnosis, treatment, management, or monitoring of diseases or conditions when supported by medical and scientific evidence. The bill specifies that coverage must be provided in a manner that minimizes disruptions in care, such as avoiding multiple biopsies. The requirements apply to individual, group, and health benefit plans, excluding certain limited benefit policies.